Trial Profile

Randomized, double-blinded, placebo-controlled, dose ranging study to assess the immunogenicity and safety of LT [heat-labile enterotoxin of E. coli; Escherichia coli vaccine] application in healthy adults.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Heat-labile enterotoxin E coli (Primary)
Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
Focus Pharmacodynamics
Sponsors Intercell USA; Valneva USA

11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
07 Sep 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
07 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com